Which are the leading cardiac marker testing business players?

Abbott, Becton, Dickinson and Company, Biom Read More

Home > Healthcare > Medical Devices > Diagnostic Devices > Cardiac Marker Testing Market

Cardiac Marker Testing Market Trends

Report ID: GMI5614
Published Date: May 2023
Report Format: PDF

Download Free Sample

Cardiac Marker Testing Market Trends

Significant increase in number of patients suffering from cardiovascular diseases such as myocardial infarction, congestive heart failure, and acute coronary syndrome among others will primarily drive the market growth over the forecast period. According to the World Health Organization report 2021, around 17.9 million people die from cardiovascular disease each year and 85% of these deaths are due to stroke and heart attacks. Increasing incidence of such diseases fuel the demand for cardiac biomarker testing procedures. Increasing geriatric population suffering from various cardiovascular diseases will significantly drive the market growth. The use of advanced cardiac biomarker testing product helps to offer efficient treatment, thereby reducing the risk of stroke.

Authors: Mariam Faizullabhoy

Frequently Asked Questions (FAQ) :

Market size for cardiac marker testing was worth USD 8.5 billion in 2022 and will observe over 7.5% CAGR from 2023-2032 due to the growing burden of cardiovascular diseases worldwide.

Cardiac marker testing industry size from congestive heart failures may witness 8.9% CAGR from 2023-2032 owing to the rising rate of congestive heart failures and associated deaths.

North America market for cardiac marker testing will record more than USD 8 billion by 2032 due to the strong presence of major business players in the region.

Abbott, Becton, Dickinson and Company, Biom